FDA
-
-
-
-
-
-
-
Mind Medicine (MNMD) to Resume Trading at 8 a.m. Following Positive Data from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
-
-
-
-
-
-
-
FCM Plans for Mind Medicine's (MNMD) MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
-
-
-
-
-
-
-
MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
-
-
-
-
-
-
-
Mind Medicine (MNMD) Appoints Francois Lilienthal as COO
-
-
-
-
-
-
-
Mind Medicine (MNMD) Announces Clinical Hold on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder
-
-
-
-
-
-
-
MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial
-
-
-
251,761 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All